Online inquiry

IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5962MR)

This product GTTS-WQ5962MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IGHE gene. The antibody can be applied in Allergic diseases research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NC_000014.9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3497
UniProt ID P01854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ5962MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9970MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA KBSA301
GTTS-WQ10046MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ4790MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BT 5/9
GTTS-WQ4463MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ6375MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ12350MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ14175MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA REGN-910
GTTS-WQ2129MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALD-403
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW